Catalent, Inc. is a holding company ... Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing ...
Catalent, Inc. (NYSE: CTLT), the leader in enabling ... Partner closely with you to successfully bring your products through development and clinical trials, and reliably supply your needs for ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
Reuters on MSN25d
Consumer groups ask FTC to block Novo Holdings-Catalent dealA Catalent spokesperson reiterated the ... but said that the drugmaker has secured near-term supplies for its clinical trials ...
“These efforts are critical to ensure a consistent and high-quality supply of NUZ-001 for both clinical trials and future ...
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...
Catalent’s remaining network of nearly ... successfully bring your products through development and clinical trials, and reliably supply your needs for commercial product launch and beyond ...
NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback